Bayer shares surge after US Supreme Court blocks glyphosate warning lawsuits

The U.S. Supreme Court voted 7‑2 in *Monsanto Co. v. Durnell* to hold that federal pesticide law preempts state‑level failure‑to‑warn claims for glyphosate. The ruling bars states from requiring a cancer warning on Roundup labels, eliminating a primary legal route for roughly 170,000 pending lawsuits, with about 3,900 still in federal court.

Bayer AG’s stock responded sharply, jumping 15‑23 % across U.S. and European markets—its biggest weekly rise since 2003—and climbing toward a 12‑month high. Analysts raised price targets, with DZ Bank lifting its goal to €54, Jefferies to €46, and Goldman Sachs maintaining €55. The decision removes a major future liability but does not affect existing settlement payments of more than $6 bn or the pending $7.25 bn settlement slated for a July 9, 2026 hearing.

The verdict was welcomed by the Trump administration and industry groups, while the “Make America Healthy Again” (MAHA) activists condemned it as a betrayal. Bayer’s balance sheet still shows €32.5 bn of net debt and negative free cash flow, so the win eases but does not erase financial pressures.

Political fallout includes calls for new legislation to curb pesticide‑producer liability, underscoring the case’s broader regulatory and public‑health implications.